Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – Q1 2020

GlobalData's “Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – Q1 2020” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2020. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2020 10

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2020 10

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2020 12

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2020 13

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2020 14

2.4.1 Upjohn Raises USD10.9 Billion in Private Placement of Notes 14

2.4.2 Takeda Pharma Prices Public Offering of Notes for USD7 Billion 14

2.4.3 Regeneron Pharma Raises USD6.7 Billion in Public Offering of Shares 15

2.4.4 Merck Raises USD4.5 Billion in Public Offering of Notes 15

2.4.5 Pfizer Raises USD4 Billion in Public Offering of Notes 15

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 16

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2020 16

3.1.1 Top M&A Deals in Q2 2020 17

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2019 – Q2 2020 18

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2020 19

3.2.1 Top Initial Public Offerings in Q2 2020 20

3.2.2 Top Secondary Offerings in Q2 2020 20

3.2.3 Top PIPE Deals in Q2 2020 21

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2019 – Q2 2020 21

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2020 23

3.3.1 Top Venture Financing Deals in Q2 2020 24

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2020 25

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2020 26

3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2019 – Q2 2020 27

3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q2 2019 – Q2 2020 28

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2019 – Q2 2020 29

3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2020 30

3.5.1 Top Private Equity Deals in Q2 2020 31

3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2019 – Q2 2020 31

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2020 33

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2020 33

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2019 – Q2 2020 34

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2020 36

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2020 37

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2020 37

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2020 38

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 39

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2019 – Q2 2020 40

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2019 – Q2 2020 41

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 42

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2020 44

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2020 44

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 45

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2020 46

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2020 46

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2020 47

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2019 – Q2 2020 48

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2019 – Q2 2020 49

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deals, Q2 2019 – Q2 2020 51

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2019 – Q2 2020 52

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2019 – Q2 2020 54

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2020 56

6.1.1 Oncology – Deals of the Quarter 57

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2020 59

6.2.1 Central Nervous System – Deals of the Quarter 60

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2020 62

6.3.1 Infectious Disease – Deals of the Quarter 63

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2020 65

6.4.1 Immunology – Deals of the Quarter 66

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2020 68

6.5.1 Metabolic Disorders – Deals of the Quarter 69

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2020 72

6.6.1 Cardiovascular – Deals of the Quarter 73

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2020 75

6.7.1 Gastrointestinal – Deals of the Quarter 76

6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2020 78

6.8.1 Dermatology – Deals of the Quarter 80

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2020 81

6.9.1 Respiratory – Deals of the Quarter 82

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2020 84

6.10.1 Ophthalmology – Deals of the Quarter 85

7 Deal Summary by Geography 87

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2020 87

7.1.1 North America – Deals of the Quarter 89

7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2020 90

7.2.1 Europe – Deals of the Quarter 91

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2020 93

7.3.1 Asia-Pacific – Deals of the Quarter 94

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2020 96

7.4.1 Rest of the World – Deals of the Quarter 97

8 Pharmaceuticals & Healthcare, Global, Top Advisors 99

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2019 – Q2 2020 99

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2019 – Q2 2020 100

9 Further Information 101

9.1 Methodology 101

9.2 About GlobalData 102

9.3 Contact Us 102

9.4 Disclosure information 102

9.5 Disclaimer 103

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 11

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2020 13

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2020 14

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 17

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2020 17

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2019 – Q2 2020 18

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 20

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2020 20

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2020 20

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2020 21

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 22

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 24

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2020 24

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2020 26

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 27

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 28

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2019 – Q2 2020 29

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 30

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2020 31

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 32

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 34

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 35

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 36

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2020 37

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2020 37

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2020 38

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 39

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2019 – Q2 2020 41

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 43

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 44

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 45

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2020 46

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2020 46

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2020 47

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 48

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2019 – Q2 2020 50

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Q2 2019 – Q2 2020 53

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 55

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 57

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 60

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 63

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 66

Table 43:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 69

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 73

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 76

Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 79

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 82

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 85

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 88

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 91

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 94

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 97

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 99

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 100

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2020 12

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q2 2020 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 16

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q2 2019 – Q2 2020 18

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 19

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q2 2019 – Q2 2020 21

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 23

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q2 2020 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q2 2020 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2019 – Q2 2020 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 28

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 30

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q2 2019 – Q2 2020 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 33

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 39

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2019 – Q2 2020 40

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2019 – Q2 2020 41

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2019 – Q2 2020 42

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 44

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 45

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 48

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 49

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q2 2019 – Q2 2020 51

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q2 2019 – Q2 2020 52

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 – Q2 2020 54

Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 56

Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 59

Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 62

Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 65

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 68

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 72

Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 75

Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 78

Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 81

Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 84

Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 87

Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 90

Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 93

Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 96

Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 99

Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2019 – Q2 2020 100

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports